Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

Why partnering for new modalities is all about proof of mechanism
BioCentury | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

Why Alkahest thinks plasma factors are key to fighting age-related diseases
BioCentury | Jul 20, 2015
Clinical News

Bertilimumab: Phase II started

BioCentury | Sep 29, 2014
Clinical News

Bertilimumab: Phase II started

BioCentury | Aug 18, 2014
Clinical News

Bertilimumab: Phase II started

BioCentury | Mar 4, 2013
Clinical News

Bertilimumab: Phase II start

BioCentury | Jun 25, 2009
Targets & Mechanisms

Seeing CNV sooner

BioCentury | Jun 18, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

Items per page:
1 - 10 of 11